Cargando…
Plasmodium vivax Sub-Patent Infections after Radical Treatment Are Common in Peruvian Patients: Results of a 1-Year Prospective Cohort Study
BACKGROUND: There is an increasing body of literature reporting treatment failure of the currently recommended radical treatment of Plasmodium vivax infections. As P. vivax is the main malaria species outside the African continent, emerging tolerance to its radical treatment regime could have major...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3030575/ https://www.ncbi.nlm.nih.gov/pubmed/21297986 http://dx.doi.org/10.1371/journal.pone.0016257 |
_version_ | 1782197278487871488 |
---|---|
author | Van den Eede, Peter Soto-Calle, Veronica E. Delgado, Christopher Gamboa, Dionicia Grande, Tanilu Rodriguez, Hugo Llanos-Cuentas, Alejandro Anné, Jozef D'Alessandro, Umberto Erhart, Annette |
author_facet | Van den Eede, Peter Soto-Calle, Veronica E. Delgado, Christopher Gamboa, Dionicia Grande, Tanilu Rodriguez, Hugo Llanos-Cuentas, Alejandro Anné, Jozef D'Alessandro, Umberto Erhart, Annette |
author_sort | Van den Eede, Peter |
collection | PubMed |
description | BACKGROUND: There is an increasing body of literature reporting treatment failure of the currently recommended radical treatment of Plasmodium vivax infections. As P. vivax is the main malaria species outside the African continent, emerging tolerance to its radical treatment regime could have major consequences in countries like Peru, where 80% of malaria cases are due to P. vivax. Here we describe the results of a 1-year longitudinal follow up of 51 confirmed P. vivax patients living around Iquitos, Peruvian Amazon, and treated according to the Peruvian national guidelines. METHODOLOGY: Each month a blood sample for microscopy and later genotyping was systematically collected. Recent exposure to infection was estimated by detecting antibodies against the P. vivax circumsporozoite protein (CSP) and all PCR confirmed P. vivax infections were genotyped with 16 polymorphic microsatellites. RESULTS: During a 1-year period, 84 recurrent infections, 22 positive also by microscopy, were identified, with a median survival time to first recurrent infection of 203 days. Most of them (71%) were asymptomatic; in 13 patients the infection persisted undetected by microscopy for several consecutive months. The genotype of mostly recurrent infections differed from that at day 0 while fewer differences were seen between the recurrent infections. The average expected heterozygosity was 0.56. There was strong linkage disequilibrium (I(A)(s) = 0.29, p<1.10(−4)) that remained also when analyzing only the unique haplotypes, suggesting common inbreeding. CONCLUSION: In Peru, the P. vivax recurrent infections were common and displayed a high turnover of parasite genotypes compared to day 0. Plasmodium vivax patients, even when treated according to the national guidelines, may still represent an important parasite reservoir that can maintain transmission. Any elimination effort should consider such a hidden reservoir. |
format | Text |
id | pubmed-3030575 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-30305752011-02-04 Plasmodium vivax Sub-Patent Infections after Radical Treatment Are Common in Peruvian Patients: Results of a 1-Year Prospective Cohort Study Van den Eede, Peter Soto-Calle, Veronica E. Delgado, Christopher Gamboa, Dionicia Grande, Tanilu Rodriguez, Hugo Llanos-Cuentas, Alejandro Anné, Jozef D'Alessandro, Umberto Erhart, Annette PLoS One Research Article BACKGROUND: There is an increasing body of literature reporting treatment failure of the currently recommended radical treatment of Plasmodium vivax infections. As P. vivax is the main malaria species outside the African continent, emerging tolerance to its radical treatment regime could have major consequences in countries like Peru, where 80% of malaria cases are due to P. vivax. Here we describe the results of a 1-year longitudinal follow up of 51 confirmed P. vivax patients living around Iquitos, Peruvian Amazon, and treated according to the Peruvian national guidelines. METHODOLOGY: Each month a blood sample for microscopy and later genotyping was systematically collected. Recent exposure to infection was estimated by detecting antibodies against the P. vivax circumsporozoite protein (CSP) and all PCR confirmed P. vivax infections were genotyped with 16 polymorphic microsatellites. RESULTS: During a 1-year period, 84 recurrent infections, 22 positive also by microscopy, were identified, with a median survival time to first recurrent infection of 203 days. Most of them (71%) were asymptomatic; in 13 patients the infection persisted undetected by microscopy for several consecutive months. The genotype of mostly recurrent infections differed from that at day 0 while fewer differences were seen between the recurrent infections. The average expected heterozygosity was 0.56. There was strong linkage disequilibrium (I(A)(s) = 0.29, p<1.10(−4)) that remained also when analyzing only the unique haplotypes, suggesting common inbreeding. CONCLUSION: In Peru, the P. vivax recurrent infections were common and displayed a high turnover of parasite genotypes compared to day 0. Plasmodium vivax patients, even when treated according to the national guidelines, may still represent an important parasite reservoir that can maintain transmission. Any elimination effort should consider such a hidden reservoir. Public Library of Science 2011-01-28 /pmc/articles/PMC3030575/ /pubmed/21297986 http://dx.doi.org/10.1371/journal.pone.0016257 Text en Van den Eede et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Van den Eede, Peter Soto-Calle, Veronica E. Delgado, Christopher Gamboa, Dionicia Grande, Tanilu Rodriguez, Hugo Llanos-Cuentas, Alejandro Anné, Jozef D'Alessandro, Umberto Erhart, Annette Plasmodium vivax Sub-Patent Infections after Radical Treatment Are Common in Peruvian Patients: Results of a 1-Year Prospective Cohort Study |
title |
Plasmodium vivax Sub-Patent Infections after Radical Treatment Are Common in Peruvian Patients: Results of a 1-Year Prospective Cohort Study |
title_full |
Plasmodium vivax Sub-Patent Infections after Radical Treatment Are Common in Peruvian Patients: Results of a 1-Year Prospective Cohort Study |
title_fullStr |
Plasmodium vivax Sub-Patent Infections after Radical Treatment Are Common in Peruvian Patients: Results of a 1-Year Prospective Cohort Study |
title_full_unstemmed |
Plasmodium vivax Sub-Patent Infections after Radical Treatment Are Common in Peruvian Patients: Results of a 1-Year Prospective Cohort Study |
title_short |
Plasmodium vivax Sub-Patent Infections after Radical Treatment Are Common in Peruvian Patients: Results of a 1-Year Prospective Cohort Study |
title_sort | plasmodium vivax sub-patent infections after radical treatment are common in peruvian patients: results of a 1-year prospective cohort study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3030575/ https://www.ncbi.nlm.nih.gov/pubmed/21297986 http://dx.doi.org/10.1371/journal.pone.0016257 |
work_keys_str_mv | AT vandeneedepeter plasmodiumvivaxsubpatentinfectionsafterradicaltreatmentarecommoninperuvianpatientsresultsofa1yearprospectivecohortstudy AT sotocalleveronicae plasmodiumvivaxsubpatentinfectionsafterradicaltreatmentarecommoninperuvianpatientsresultsofa1yearprospectivecohortstudy AT delgadochristopher plasmodiumvivaxsubpatentinfectionsafterradicaltreatmentarecommoninperuvianpatientsresultsofa1yearprospectivecohortstudy AT gamboadionicia plasmodiumvivaxsubpatentinfectionsafterradicaltreatmentarecommoninperuvianpatientsresultsofa1yearprospectivecohortstudy AT grandetanilu plasmodiumvivaxsubpatentinfectionsafterradicaltreatmentarecommoninperuvianpatientsresultsofa1yearprospectivecohortstudy AT rodriguezhugo plasmodiumvivaxsubpatentinfectionsafterradicaltreatmentarecommoninperuvianpatientsresultsofa1yearprospectivecohortstudy AT llanoscuentasalejandro plasmodiumvivaxsubpatentinfectionsafterradicaltreatmentarecommoninperuvianpatientsresultsofa1yearprospectivecohortstudy AT annejozef plasmodiumvivaxsubpatentinfectionsafterradicaltreatmentarecommoninperuvianpatientsresultsofa1yearprospectivecohortstudy AT dalessandroumberto plasmodiumvivaxsubpatentinfectionsafterradicaltreatmentarecommoninperuvianpatientsresultsofa1yearprospectivecohortstudy AT erhartannette plasmodiumvivaxsubpatentinfectionsafterradicaltreatmentarecommoninperuvianpatientsresultsofa1yearprospectivecohortstudy |